Bovine respiratory disease (BRD) continues to be a leading cause of economic loss, hampered animal welfare, and intensive antimicrobial use in cattle operations worldwide. Reduction of antimicrobial use is hindered because it is still unclear which clinical signs are best monitored to reliably detect pneumonia. Also, these clinical signs may vary according to age and between breeds. The objective of this cross-sectional study was to identify clinical signs associated with ultrasound-confirmed pneumonia (lung consolidation ≥1 cm depth) pre-and postweaning in different production types (dairy, beef, and veal) and breeds. A total of 956 calves (70% Holstein-Friesian dairy and 30% Belgian Blue beef) from 84 herds were clinically examined using 24 parameters, scored using the Wisconsin and California BRD clinical scoring systems and subjected to thoracic ultrasonography. Of the calves, 42.8% and 19.5% had a lung consolidation ≥1 cm and ≥3 cm, respectively. Cough, both spontaneous and induced, was the only and best-performing clinical sign statistically associated with lung consolidation in all production types. Fever (rectal temperature ≥39.4°C) was the second most promising factor, being significant in beef and veal calves but not in dairy calves. Postweaning, none of the clinical signs studied were statistically associated with pneumonia, with the exception of cough in dairy calves. Spontaneous or induced cough as a single clinical sign outperformed any combination of clinical signs, including the Wisconsin and California respiratory disease scoring systems, but sensitivity remained low. This information can be useful to select appropriate clinical signs for continuous monitoring in precision livestock applications, targeted to a given breed and age. As a cross-sectional measurement, diagnostic accuracy of spontaneous cough (accuracy = 65.1%, sensitivity = 37.4%, specificity = 85.7%) is too low to be used as a criterion to select animals with pneumonia for antimicrobial treatment. At the group level, cough monitoring holds potential as an early warning sign, after which lung ultrasonography should follow.
Background Respiratory infections are the main indication for antimicrobial use in calves. Optimal treatment duration currently is unknown, but shorter duration would likely decrease selection for antimicrobial resistance. Hypothesis/Objectives Determine differences in cure rate and healing time between animals treated with florfenicol and oxytetracycline in a natural outbreak of respiratory disease using reaeration observed on thoracic ultrasound examination as healing criterion. Animals Commercial farm housing 130, 3 to 9 month old Belgian blue beef calves. Methods Randomized clinical trial during an outbreak of respiratory disease. Metaphylactic treatment was initiated, randomly treating animals with either florfenicol or oxytetracycline. Ultrasonographic follow‐up was done the first day and every other day for a 14‐day period. At the individual animal level, treatment was discontinued when reaeration of the lungs occurred. Differences in cure rate and healing time were determined. Results Of the 130 animals studied, 67.7% developed a lung consolidation ≥0.5 cm. The mean ultrasonographic healing time was 2.5 days in the florfenicol group compared to 3.1 days in the oxytetracycline group (P = .04). After single treatment, 80.6% and 60.3% had no consolidations in the florfenicol and oxytetracycline groups, respectively (P = .01). A Mycoplasma bovis strain was genetically and phenotypically determined to be susceptible to both antimicrobials. Conclusions and Clinical Importance Ultrasonographic lung reaeration shows potential as a cure criterion to rationalize antimicrobial use for outbreaks of pneumonia. In our study, florfenicol resulted in a faster cure and higher reduction in antimicrobial usage than did oxytetracycline.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.